Closing Bell Movers: Gap down 15%, Elastic off by 11% on earnings
In the opening hour of the evening session, U.S. equity futures are down slightly, with S&P 500 e-minis down 0.2% at 5,911, Nasdaq 100 down 0.3% at 21,353, and Dow Industrials off by 0.1% at 42,221. In commodities, WTI Crude Oil is down marginally below $61 per barrel, remaining in a tight $3 range for the past two weeks. In precious metals, Gold is off by 0.2% below $3,340 per ounce following Thursday's bullish action but also locked in a sideways trading pattern.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Stocks were able to preserve overnight gains on Thursday spurred by the ruling of the U.S. Court of International Trade invalidating Trump's tariff agenda, though today's ruling by an Appellate court has suppressed that decision. Real Estate, Health Care, and Utilities were the best performing sectors on the S&P as Treasury yields fell steeply. Communication services underperformed however, with weakness in Netflix, Gaming companies, and Cable names.
In earnings, Computer Hardware space saw mixed performance with a slight post-earnings rally by Dell but a sizable post-earnings decline in NetApp shares.
Check out this evening's top movers from around Wall Street, compiled by The Fly.
HIGHER AFTER EARNINGS –
Red Robin Gourmet Burgers (RRGB) up 54.6%
UiPath (PATH) up 9.4%
Ulta Beauty (ULTA) up 8.3%
Zscaler (ZS) up 3.5%
Dell Technologies (DELL) up 1.7%
DOWN AFTER EARNINGS –
American Eagle Outfitters (AEO) down 7.5%
NetApp (NTAP) down 5.5%
PagerDuty (PD) down 3.7%
Marvell (MRVL) down 2.7%
Costco (COST) down 0.4%
ALSO LOWER –
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Elon Musk Thinks Tesla Will Be the World's Most Valuable Company, but This Huge Problem Could Send Its Stock Plunging by 70% Instead
Self-driving cars and humanoid robots are key to Musk's bullish vision for Tesla, but the company has to overcome major challenges first. Tesla's electric vehicle sales are plummeting, and continued weakness could lead to massive losses for the stock. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) stock hit a new record high in Dec. 2024 on the back of President Trump's election win. Investors speculated that Trump's focus on deregulation could speed up the company's ability to commercialize its autonomous robotaxi and humanoid robot opportunities. In fact, CEO Elon Musk believes those two businesses will eventually make Tesla the world's most valuable company one day -- potentially even more valuable than the next five companies combined. Today, those five companies are Microsoft, Apple, Nvidia, Amazon, and Alphabet, and they have a combined market capitalization of $13.6 trillion. But there's a problem: Tesla is worth only $1.2 trillion as of this writing, and most of its revenue still comes from selling electric vehicles (EVs), which are seeing plummeting demand. That's bad news for Musk's ambitious forecast in the near term, and here's why it could lead to a collapse of over 70% for Tesla stock instead. Back in 2023, Musk told investors Tesla could grow its EV production 50% annually for the foreseeable future. Deliveries hit a record high of 1.81 million vehicles that year, a year-over-year increase of 38%. But in 2024, deliveries shrank by 1% to 1.79 million. Simply put, Tesla can't grow production 50% per year if sales aren't keeping up. Unfortunately, the situation appears to be getting worse: Deliveries plunged even further in the first quarter of 2025, this time by 13%. And there could be an even sharper decline in the second quarter if the available data from April is accurate. In the United Kingdom, new Tesla EV registrations fell 62% year over year in April. There were also sharp declines across Europe -- registrations collapsed 81% in Sweden, 74% in the Netherlands, 67% in Denmark, and 59% in France. Analyst estimates indicate Tesla might deliver as little as 350,000 cars during the second quarter, or a year-over-year drop of more than 20%. The problem seems to be specific to Tesla because EV sales overall soared 28% across Europe in April. Chinese automaker BYD saw a staggering 359% increase in sales across the region, and it sold more cars than Tesla for the first time ever during the month. BYD is known for its ultra-affordable models, like the Seagull, which sells for under $10,000 in China. Tesla simply can't compete at that price point. Musk's political affiliations might also be damaging the brand, mainly because of his work within the Trump administration's Department of Government Efficiency. Musk helped slash thousands of federal jobs and shuttered entire agencies. According to the most recent CNBC All-America Economic survey, around half of Americans now have a negative view of Musk, while only 36% view him positively. That public opinion flowed through to Tesla with 47% of respondents expressing a negative view of the company. Last October, Tesla unveiled its long-awaited Cybercab robotaxi. It has no pedals or steering wheel because it's designed to run entirely on the company's Full Self-Driving (FSD) software. Musk wants to build a ride-hailing network in which Cybercabs can transport passengers and earn revenue for Tesla around the clock. But the unsupervised version of Tesla's FSD isn't approved for use on public roads yet. Musk says the company could offer paid autonomous rides starting in June of this year, but he doesn't expect true scale to be achieved until the second half of 2026. That places Tesla significantly behind the likes of Waymo, which is already completing over 250,000 paid autonomous trips every single week across Los Angeles, San Francisco, Phoenix, and Austin. Catching up to Waymo won't be easy because it has partnered with Uber Technologies, which operates the world's largest ride-hailing network with 170 million monthly users. It could take Tesla years to achieve that level of scale, especially if it builds its own mobility network from scratch. But Musk is eyeing another major opportunity: the Optimus humanoid robot. He says it could generate a staggering $10 trillion in revenue over the long term. Tesla will reportedly manufacture thousands of them this year to use inside its factories, but Musk predicts the company could be producing millions of them annually by 2029 or 2030. Optimus could eventually be used for the dangerous jobs and repetitive tasks that humans don't want to do, so there is an enormous addressable market across the business and consumer sectors. While Musk claims humanoid robots will outnumber humans by 2040, keep in mind the CEO is known for bold predictions that don't always come to fruition. If products like the Cybercab, FSD, and Optimus are a success, Tesla could certainly become the world's most valuable company. But it's facing a serious problem right now because its stock is trading at an eyewatering price-to-earnings (P/E) ratio of 186.5. For some perspective, Nvidia, Microsoft, Amazon, Apple, and Alphabet trade at an average P/E ratio of just 32.2: Tesla's earnings per share (EPS) plunged 71% during the first quarter of 2025, whereas each of the other five companies generated EPS growth in their most recent quarters. Tesla's premium valuation makes even less sense from that angle because investors typically assign a higher P/E ratio to companies that are growing quickly. Tesla stock would have to plummet by 76% just for its P/E ratio to trade in line with Nvidia's, and that is a legitimate risk. Despite the long-term potential of products like the Cybercab and Optimus, 72% of Tesla's revenue still comes from selling EVs, and the pace at which sales are shrinking will almost certainly drive an ongoing collapse in the company's EPS for the foreseeable future. Remember, based on Musk's optimistic predictions, it could be years before the Cybercab and Optimus businesses are generating enough revenue to offset the weakness in Tesla's EV sales. As a result, there is little hope the company will grow to exceed the combined value of Nvidia, Microsoft, Amazon, Apple, and Alphabet anytime soon. I believe the stock is destined for a sharp decline instead, bringing its P/E ratio in line with those of its big-tech peers. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $349,597!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,048!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $651,761!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of May 19, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Microsoft, Nvidia, Tesla, and Uber Technologies. The Motley Fool recommends BYD Company and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Elon Musk Thinks Tesla Will Be the World's Most Valuable Company, but This Huge Problem Could Send Its Stock Plunging by 70% Instead was originally published by The Motley Fool
Yahoo
40 minutes ago
- Yahoo
Down Over 30%: Wells Fargo Says Now Is the Time to Load Up on These 2 Beaten-Down Stocks
Stock prices can tumble for all sorts of reasons, but not every beaten-down stock deserves to be written off. Some are weighed down by weak fundamentals or lackluster performance, while others are simply caught in the broader market tide. When a company's core business remains strong, a dip in its share price might just be a golden opportunity in disguise. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Finding those diamonds in the rough is what separates the savvy investors from the rest. Hone this skill, and you're well on your way to building a portfolio with serious upside. It's the classic strategy: buy low, sell high – easier said than done, but worth mastering. Wells Fargo's analysts are putting that strategy to work. They've pinpointed a pair of stocks that are down more than 30% this year, but still earn a bullish 'Buy' rating. Backed by TipRanks data, we'll take a closer look at why these names have caught the analysts' attention. Let's get into it. RxSight (RXST) The first stock we'll look at here is RxSight, a medical technology company that focuses on the eye – specifically, on the lens of the eye. The company has developed the first, and so far, the only, synthetic intraocular lens that can be adjusted and customized after cataract surgery. In cataract surgeries, a clouded natural lens is removed from the eye and replaced with a synthetic substitute. Because this replacement lens is normally 'fixed,' that is, does not self-adjust the way a natural lens does, patients typically don't experience a return to completely normal vision. RxSight's product, the Light Adjustable Lens (LAL), allows for post-surgical adjustments, using precise UV light treatments. This approach allows the ophthalmologist to 'fine-tune' the lens after the patient has recovered from the surgery, and after natural post-surgical shifting and refractive changes have occurred. By delaying the lens adjustments in this fashion, the patient can be given a better-adjusted lens for more accurate vision. This company has advanced its product to the commercial stage. It received FDA approval for the LAL product line in 2017, and has been marketing the product ever since. In the last reported period, 1Q25, the company brought in $37.9 million in product revenue, up 28.5% year-over-year and about in-line with analyst expectations. At the bottom line, the company ran a net loss of 3 cents per share by non-GAAP measures. This net loss came in 5 cents per share better than had been expected. For the full-year 2025, the company is predicting revenue in the range of $160 million to $175 million, which would represent year-over-year growth between 14% and 25%. That guide represented a reduction; the previously published guidance range had been set at $185.0 million to $197.0 million. The stock fell sharply by nearly 40% after the guidance was revised downward back in April. For the year-to-date, shares in RXST are down 53%. For Wells Fargo analyst Larry Biegelsen, the key points here are RxSight's revenue potential and the sound risk-reward profile. He writes, 'Our Overweight rating on RXST reflects the company's first-in-class IOL technology that can be customized after cataract surgery and its growth opportunity in the multi-billion-dollar premium IOL market where the company holds a significant first-mover advantage. In addition, we see incremental revenue opportunities from the coming wave of post-LASIK patients and international expansion. At current valuation levels, we see an attractive risk-reward profile for RXST shares… RXST currently trades at 2.0x consensus 2025 sales, or >50% discount to SMID cap peers. RXST has above average growth, a strong moat, & relatively high gross margins which should increase over time. Therefore, we think it should trade at least at a market multiple.' That Overweight (i.e., Buy) rating is backed up by a $25 price target, implying a one-year upside potential of 54%. (To watch Biegelsen's track record, click here) RxSight has picked up a Moderate Buy consensus rating based on 10 recent analyst reviews, including 5 Buys, 3 Holds, and 2 Sells. The shares are priced at $16.23 and their $25.30 average target price indicates room for an upside of 56% this coming year. (See RXST stock forecast) Omnicell (OMCL) California-based Omnicell, the second stock on our list here, has been working in the medical field since 1992. The company is known as a leader in the field of autonomous pharmacy technology, using a combination of smart devices, robotics, and software to improve efficiencies, cost savings, and supply chain controls in the global pharmacy sector. Omnicell's devices, tools, and methods are particularly popular among hospital and other institutional pharmacy settings. Autonomous pharmacy tech, Omnicell's specialty, plays a vital role in the medical field, improving patient outcomes by improving compliance with prescription directions. Omnicell's systems allow for clearer, more accurate prescription fills, giving improved medication packaging, better regulatory compliance, and even allowing additional tools for patients to manage medication. Distribution errors in medication can have serious, even severe, repercussions for patients, and Omnicell provides medical providers with the tools and technology to minimize those errors. Chief among the company's product lines is the XT Amplify Automated Dispensing System. In its earnings release for 1Q25, Omnicell reported a 10% year-over-year gain in revenue to $270 million, beating the forecast by almost $10 million. At the bottom line, Omnicell's non-GAAP EPS came to 26 cents, or 6 cents per share better than the estimates, based on a total non-GAAP quarterly net income of $12 million. The company finished the quarter with a balance sheet featuring $387 million in cash and liquid assets, $341 million in total debt, and $2.2 billion in total assets. We should note here that shares in Omnicell are down for the year. OMCL stock has fallen 33% so far in 2025 – due in part to concerns over the company's exposure to tariffs. That share price drop hasn't stopped analyst Stan Berenshteyn from taking an upbeat view of this stock. In his coverage for Wells Fargo, the analyst says of OMCL, 'We see Omnicell as a leading strategic vendor of pharmacy automation solutions for health systems. While we see some more near-term drag from XT upgrade reaching an end, we see a path for Bookings acceleration in 2026 from upgrades and robot adoption and think at least partial tariff resolution should drive upside momentum to EBITDA estimates beyond 2025… While tariff risks remain fluid, we believe trade talks will likely steer outcomes toward the lower end of the risk range, supporting a more optimistic stance.' Quantifying his stance, Berenshteyn gives the stock an Overweight (Buy) rating, and his price target of $37 points toward a 12-month gain of 24%. (To watch Berenshteyn's track record, click here) This stock's Moderate Buy consensus rating is based on 6 recent reviews that break down to 4 Buys and 2 Holds. The shares have a current trading price of $29.83 and the average target price, at $40.40, suggests that the stock will gain 35.5% by this time next year. (See OMCL stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
1 Thing Investors Must Know Before Buying the 52% Dip on UnitedHealth Group
The problems at UnitedHealth Group are piling up, including alleged criminal activity. The stock could face government intervention in a worst-case scenario. UnitedHealth Group probably won't revisit highs anytime soon. 10 stocks we like better than UnitedHealth Group › Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,263!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. 1 Thing Investors Must Know Before Buying the 52% Dip on UnitedHealth Group was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
